ESMO 2018 | Is CAR T-cell therapy for solid malignancies?
Michel Sadelain
CAR T-cell therapy has good prospects for moving into the field of solid tumors, suggests Michel Sadelain, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. With adjustments, particularly for the tumor microenvironments, Dr Sadelain believes it will be possible to use CAR-T technology in the solid setting.
Related videos
1:50
Prof. Kelly’s overview of the RECaN project
Daniel Kelly
1:28
Meaningful, patient-centered research
John Gore
1:47
The importance of patient education
Hendrik Van Poppel
3:32
Accelerate, Coordinate, Evaluate (ACE) cancer care: the CRUK programme streamlining the care pathway
Sara Hiom
1:26
MR Linac: benefits, usage & research collaborations
Fiona McDonald
